Chemopreventive effects of tolfenamic acid against esophageal tumorigenesis in rats

Investigational New Drugs

Volumn 30, Issue 3, 2012, Pages 853-861

  Maliakal, Pius ^a   Abdelrahim, Maen ^a   Sankpal, Umesh T ^a   Maliakal, Cima ^a   Baker, Cheryl H ^a   Safe, Stephen ^b   Herrera, Luis J ^a   Abudayyeh, Ala ^c   Kaja, Sumanth ^a   Basha, Riyaz ^a  

^a M D ANDERSON CANCER CENTER ORLANDO   (United States)

^b TEXAS A AND M UNIVERSITY   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

c Met; Esophageal cancer; Esophageal cancer prevention; N nitrosomethylbenzylamine; Sp1; Tolfenamic acid

Indexed keywords

SCATTER FACTOR RECEPTOR; TOLFENAMIC ACID; TRANSCRIPTION FACTOR SP;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CANCER PREVENTION; CARCINOGENESIS; CELL VIABILITY; CHEMOPROPHYLAXIS; CONTROLLED STUDY; DRUG MECHANISM; ESOPHAGUS CANCER; HUMAN; HUMAN CELL; MITOSIS INHIBITION; NONHUMAN; PRIORITY JOURNAL; RAT; TUMOR VOLUME;

ANIMALS; ANTICARCINOGENIC AGENTS; CARCINOGENS; CELL LINE; CELL SURVIVAL; DIMETHYLNITROSAMINE; DISEASE MODELS, ANIMAL; ESOPHAGEAL NEOPLASMS; HUMANS; ORTHO-AMINOBENZOATES; PROTO-ONCOGENE PROTEINS C-MET; RATS; RATS, INBRED F344; SP TRANSCRIPTION FACTORS; TUMOR BURDEN;

EID: 84864366217     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-010-9622-0     Document Type: Article

References (62)

1. Walsh TN, Noonan N, Hollywood D, Kelly A, Keeling N, Hennessy TP (1996) A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N Engl J Med 335:462-467 (Pubitemid 26269945)
2. Parkin DM, Bray FI, Devesa SS (2001) Cancer burden in the year 2000. The global picture. Eur J Cancer 37(Suppl 8):S4-S66
3. Vaughan TL, Dong LM, Blount PL, Ayub K, Odze RD, Sanchez CA, Rabinovitch PS, Reid BJ (2005) Non-steroidal anti-inflammatory drugs and risk ofneoplastic progression in Barrett's oesophagus: a prospective study. Lancet Oncol 6:945-952 (Pubitemid 41685227)
4. Tuyns AJ, Pequignot G, Abbatucci JS (1979) Oesophageal cancer and alcohol consumption; importance of type of beverage. Int J Cancer 23:443-447 (Pubitemid 9170890)
5. Yang CS (1980) Research on esophageal cancer in China: a review. Cancer Res 40:2633-2644
6. Stoner GD, Gupta A (2001) Etiology and chemoprevention of esophageal squamous cell carcinoma. Carcinogenesis 22:1737-1746 (Pubitemid 33064837)
7. Wynder EL, Bross IJ (1961) A study of etiological factors in cancer of the esophagus. Cancer 14:389-413
8. Aisner J, Arriagada R, Green MR, Martini N, Perry MC (eds) (1996) Lung and esophageal carcinogenesis. Willilams and Wilkins, Baltimore
9. Liston BW, Nines R, Carlton PS, Gupta A, Aziz R, Frankel W, Stoner GD (2003) Perillyl alcohol as a chemopreventive agent in N- nitrosomethylbenzylamine-induced rat esophageal tumorigene-sis. Cancer Res 63:2399-2403 (Pubitemid 36605175)
10. Balansky RM, Ganchev G, D'Agostini F, De Flora S (2002) Effects of N-acetylcysteine in an esophageal carcinogenesis model in rats treated with diethylnitrosamine and diethyldithiocarbamate. Int J Cancer 98:493-497. doi:10.1002/ijc.10215 (Pubitemid 34208548)
11. Stoner GD, Morse MA (1997) Isothiocyanates and plant poly-phenols as inhibitors of lung and esophageal cancer. Cancer Lett 114:113-119. doi:S0304-3835(97)04639-9 (Pubitemid 27140089)
12. Stoner GD, Wang LS, Chen T (2007) Chemoprevention of esophageal squamous cell carcinoma. Toxicol Appl Pharmacol 224:337-349 (Pubitemid 47575680)
13. Farrow DC, Vaughan TL (1996) Determinants of survival following the diagnosis of esophageal adenocarcinoma (United States). Cancer Causes Control 7:322-327 (Pubitemid 26163884)
14. Wattenberg LW (1985) Chemoprevention of cancer. Cancer Res 45:1-8 (Pubitemid 15196921)
15. Wargovich MJ, Woods C, Eng VW, Stephens LC, Gray K (1988) Chemoprevention of N-nitrosomethylbenzylamine-induced esoph-ageal cancer in rats by the naturally occurring thioether, diallyl sulfide. Cancer Res 48:6872-6875 (Pubitemid 19012220)
16. Mandal S, Stoner GD (1990) Inhibition of N-nitrosobenzylmethylamine- induced esophageal tumorigenesis in rats by ellagic acid. Carcino-genesis 11:55-61 (Pubitemid 20050736)
17. Mori Y, Tatematsu K, Koide A, Sugie S, Tanaka T, Mori H (2006) Modification by curcumin ofmutagenic activation ofcarcinogenic N-nitrosamines by extrahepatic cytochromes P-450 2B1 and 2E1 in rats. Cancer Sci 97:896-904 (Pubitemid 44151271)
18. Wilkinson JT, Morse MA, Kresty LA, Stoner GD (1995) Effect of alkyl chain length on inhibition of N-nitrosomethylbenzylamine-induced esophageal tumorigenesis and DNA methylation by isothiocyanates. Carcinogenesis 16:1011-1015
19. Wang ZY, Wang LD, Lee MJ, Ho CT, Huang MT, Conney AH, Yang CS (1995) Inhibition of N-nitrosomethylbenzylamine-induced esophageal tumorigenesis in rats by green and black tea. Carcinogenesis 16:2143-2148
20. Li ZG, Hong T, Shimada Y, Komoto I, Kawabe A, Ding Y, Kaganoi J, Hashimoto Y, Imamura M (2002) Suppression of N-nitrosomethylbenzylamine (NMBA)-induced esophageal tu-morigenesis in F344 rats by resveratrol. Carcinogenesis 23:1531-1536 (Pubitemid 35012434)
21. Chen T, Nines RG, Peschke SM, Kresty LA, Stoner GD (2004) Chemopreventive effects of a selective nitric oxide synthase inhibitor on carcinogen-induced rat esophageal tumorigenesis. Cancer Res 64:3714-3717 (Pubitemid 38657952)
22. Reddy BS, Hirose Y, Lubet R, Steele V Kelloff G, Paulson S, Seibert K, Rao CV (2000) Chemoprevention of colon cancer by specific cyclooxygenase-2 inhibitor, celecoxib, administered during different stages of carcinogenesis. Cancer Res 60:293-297 (Pubitemid 30070754)
23. Jacoby RF, Seibert K, Cole CE, Kelloff G, Lubet RA (2000) The cyclooxygenase-2 inhibitor celecoxib is a potent preventive and therapeutic agent in the min mouse model of adenomatous polyposis. Cancer Res 60:5040-5044
24. Chiu CH, McEntee MF, Whelan J (1997) Sulindac causes rapid regression of preexisting tumors in Min/+ mice independent of prostaglandin biosynthesis. Cancer Res 57:4267-4273 (Pubitemid 27413435)
25. Boolbol SK, Dannenberg AJ, Chadburn A, Martucci C, Guo XJ, Ramonetti JT, Abreu-Goris M, Newmark HL, Lipkin ML, DeCosse JJ, Bertagnolli MM (1996) Cyclooxygenase-2 over-expression and tumor formation are blocked by sulindac in a murine model of familial adenomatous polyposis. Cancer Res 56:2556-2560 (Pubitemid 26171681)
26. Wang RH, Ou-Yang Q, Chen X, Li GD, Xiang JY (2009) Chemoprevention of Barrett's esophagus by celecoxib in rats. Zhejiang Da Xue Xue Bao Yi Xue Ban 38:498-504
27. Heath EI, Canto MI, Piantadosi S, Montgomery E, Weinstein WM, Herman JG, Dannenberg AJ, Yang VW, Shar AO, Hawk E, Forastiere AA (2007) Secondary chemoprevention of Barrett's esophagus with celecoxib: results of a randomized trial. J Natl Cancer Inst 99:545-557. doi:10.1093/jnci/djk112 (Pubitemid 47073557)
28. Rocha FT, Lourenco LG, Juca MJ, Costa V, Leal AT (2009) Chemoprevention by celecoxib in reflux-induced gastric adeno-carcinoma in Wistar rats that underwent gastrojejunostomy Acta Cir Bras 24:189-194. doi:S0102- 86502009000300005
29. Bespalov VG, Troian DN, Petrov AS, Aleksandrov VA (1989) The inhibition of esophageal tumor development by the useof the nonsteroidal and steroidal anti-inflammatory preparations indo-methacin and dexamethasone. Farmakol Toksikol 52:67-70 (Pubitemid 19076183)
30. Herrera LJ, El-Hefnawy T, Queiroz de Oliveira PE, Raja S, Finkelstein S, Gooding W, Luketich JD, Godfrey TE, Hughes SJ (2005) The HGF receptor c-Met is overexpressed in esophageal adenocarcinoma. Neoplasia 7:75-84 (Pubitemid 40209473)
31. Papineni S, Chintharlapalli S, Abdelrahim M, Lee SO, Burghardt R, Abudayyeh A, Baker C, Herrera L, Safe S (2009) Tolfenamic acid inhibits esophageal cancer through repression of specificity proteins and c-Met. Carcinogenesis 30:1193-1201. doi:10.1093/carcin/bgp092
32. Higgins KJ, Abdelrahim M, Liu S, Yoon K, Safe S (2006) Regulation of vascular endothelial growth factor receptor-2 expression in pancreatic cancer cells by Sp proteins. Biochem Biophys Res Commun 345:292-301 (Pubitemid 44269283)
33. Abdelrahim M, Baker CH, Abbruzzese JL, Sheikh-Hamad D, Liu S, Cho SD, Yoon K, Safe S (2007) Regulation of vascular endothelial growth factor receptor-1 expression by specificity proteins 1, 3, and 4 in pancreatic cancer cells. Cancer Res 67:3286-3294 (Pubitemid 46724867)
34. Abdelrahim M, Newman K, Vanderlaag K, Samudio I, Safe S (2006) 3, 3'-diindolylmethane (DIM) and its derivatives induce apoptosis in pancreatic cancer cells through endoplasmic reticulum stress-dependent upregulation of DR5. Carcinogenesis 27:717-728
35. Lee SH, Bahn JH, Choi CK, Whitlock NC, English AE, Safe S, Baek SJ (2008) ESE-1/EGR-1 pathway plays a role in tolfenamic acid-induced apoptosis in colorectal cancer cells. Mol Cancer Ther 7:3739-3750
36. Otte JM, Schmitz F, Kiehne K, Stechele HU, Banasiewicz T, Krokowicz P, Nakamura T, Folsch UR, Herzig K (2000) Functional expression of HGF and its receptor in human colorectal cancer. Digestion 61:237-246 (Pubitemid 30418224)
37. Saeki H, Oda S, Kawaguchi H, Ohno S, Kuwano H, Maehara Y Sugimachi K (2002) Concurrent overexpression ofEts-1 and c-Met correlates with a phenotype of high cellular motility in human esophageal cancer. Int J Cancer 98:8-13 (Pubitemid 34113410)
38. Takada N, Yano Y, Matsuda T, Otani S, Osugi H, Higashino M, Kinoshita H, Fukushima S (1995) Expression ofimmunoreactive human hepatocyte growth factor in human esophageal squamous cell carcinomas. Cancer Lett 97:145-148
39. Zhang X, Li Y Dai C, Yang J, Mundel P, Liu Y (2003) Sp1 and Sp3 transcription factors synergistically regulate HGF receptor gene expression in kidney. Am J Physiol Renal Physiol 284:F82-F94 (Pubitemid 35471288)
40. Abdelrahim M, Smith R 3rd, Burghardt R, Safe S (2004) Role of Sp proteins in regulation of vascular endothelial growth factor expression and proliferation ofpancreatic cancer cells. Cancer Res 64:6740-6749 (Pubitemid 39297937)
41. Chen T, Rose ME, Hwang H, Nines RG, Stoner GD (2006) Black raspberries inhibit N-nitrosomethylbenzylamine (NMBA)-induced angiogenesis in rat esophagus parallel to the suppression ofCOX-2 and iNOS. Carcinogenesis 27:2301-2307 (Pubitemid 44644820)
42. Abdelrahim M, Baker CH, Abbruzzese JL, Safe S (2006) Tolfenamic acid and pancreatic cancer growth, angiogenesis, and Sp protein degradation. J Natl Cancer Inst 98:855-868 (Pubitemid 43923442)
43. Colon J, Basha MR, Madero-Visbal R, Konduri S, Baker CH, Herrera LJ, Safe S, Sheikh-Hamad D, Abudayyeh A, Alvarado B, Abdelrahim M (2009) Tolfenamic acid decreases c-Met expres-sion through Sp proteins degradation and inhibits lung cancer cells growth and tumor formation in orthotopic mice. Invest New Drugs. doi:10.1007/s10637-009-9331-8
44. Konduri S, Colon J, Baker CH, Safe S, Abbruzzese JL, Abudayyeh A, Basha MR, Abdelrahim M (2009) Tolfenamic acid enhances pancreatic cancer cell and tumor response to radiation therapy by inhibiting survivin protein expression. Mol Cancer Ther 8:533-542
45. Swann PF, Graves RJ, Mace R (1987) International Commission for Protection against Environmental Mutagens and Carcinogens. ICPEMC Working Paper No. 15/6. Effect of ethanol on nitrosamine metabolism and distribution. Implications for the role of nitrosamines in human cancer and for the influence of alcohol consumption on cancer incidence. Mutat Res 186:261-267 (Pubitemid 17146892)
46. Magee PN (1989) The experimental basis for the role of nitroso compounds in human cancer. Cancer Surv 8:207-239 (Pubitemid 20035373)
47. Lu SH, Chui SX, Yang WX, Hu XN, Guo LP, Li FM (1991) Relevance of N-nitrosamines to oesophageal cancer in China. IARC Sci Publ 105:11-17
48. Rao CV, Reddy BS (2004) NSAIDs and chemoprevention. Curr Cancer Drug Targets 4:29-42 (Pubitemid 38332562)
49. Humphrey PA, Zhu X, Zarnegar R, Swanson PE, Ratliff TL, Vollmer RT, Day ML (1995) Hepatocyte growth factor and its receptor (c-MET) in prostatic carcinoma. Am J Pathol 147:386-396
50. Gherardi E, Sharpe M, Lane K, Sirulnik A, Stoker M (1993) Hepatocyte growth factor/scatter factor (HGF/SF), the c-met receptor and the behaviour of epithelial cells. Symp Soc Exp Biol 47:163-181
51. Weidner KM, Behrens J, Vandekerckhove J, Birchmeier W (1990) Scatter factor: molecular characteristics and effect on the invasiveness ofepithelial cells. J Cell Biol 111:2097-2108
52. Jeffers M, Rong S, Vande Woude GF (1996) Enhanced tumori-genicity and invasion-metastasis by hepatocyte growth factor/scatter factor-met signalling in human cells concomitant with induction of the urokinase proteolysis network. Mol Cell Biol 16:1115-1125 (Pubitemid 26061683)
53. Rong S, Bodescot M, Blair D, Dunn J, Nakamura T, Mizuno K, Park M, Chan A, Aaronson S, Vande Woude GF (1992) Tumorigenicity of the met proto-oncogene and the gene for hepatocyte growth factor. Mol Cell Biol 12:5152-5158
54. Jeffers M, Rong S, Woude GF (1996) Hepatocyte growth factor/scatter factor-Met signaling in tumorigenicity and invasion/metastasis. J Mol Med 74:505-513 (Pubitemid 26306792)
55. Wang X, DeFrances MC, Dai Y, Pediaditakis P, Johnson C, Bell A, Michalopoulos GK, Zarnegar R (2002) A mechanism of cell survival: sequestration of Fas by the HGF receptor Met. Mol Cell 9:411-421 (Pubitemid 34195565)
56. Peng HM, Coon MJ (2000) Promoter function and the role of cytokines in the transcriptional regulation of rabbit CYP2E1 and CYP2E2. Arch Biochem Biophys 382:129-137. doi:10.1006/abbi.2000.2001
57. Coon MJ, Ding XX, Pernecky SJ, Vaz AD (1992) Cytochrome P450: progress and predictions. FASEB J 6:669-673
58. Koop DR (1992) Oxidative and reductive metabolism by cytochrome P450 2E1. FASEB J 6:724-730
59. Abdel-Razzak Z, Loyer P, Fautrel A, Gautier JC, Corcos L, Turlin B, Beaune P, Guillouzo A (1993) Cytokines down-regulate expression of major cytochrome P-450 enzymes in adult human hepatocytes in primary culture. Mol Pharmacol 44:707-715 (Pubitemid 23317282)
60. Yang CS, Smith TJ (1996) Mechanisms ofnitrosamine bioactiva-tion and carcinogenesis. Adv Exp Med Biol 387:385-394
61. Chen L, Lee M, Hong JY, Huang W, Wang E, Yang CS (1994) Relationship between cytochrome P450 2E1 and acetone catabo-lism in rats as studied with diallyl sulfide as an inhibitor. Biochem Pharmacol 48:2199-2205. doi:0006-2952(94)00435-8 (Pubitemid 24374708)
62. Kawanishi T, Ohno Y, Takahashi A, Takanaka A, Kasuya Y, Omori Y (1985) Substrate concentration dependency of N-nitrosodimethylamine and N-nitrosomethylbenzylamine metab-olism in rat liver. Carcinogenesis 6:823-827